Investor joins Microbiotica as CMO

UK-based microbiome company Microbiotica has appointed Robert Tansley its chief medical officer (CMO).

Dr Tansley steps into the role at a key development stage for Microbiotica, with its two lead programs progressing through Phase I trials in immuno-oncology—MB097 for advanced melanoma— and inflammatory bowel disease—MB310 for ulcerative colitis—with data read-outs anticipated this year.

Spun out of the Wellcome Sanger Institute in 2016, Microbiotica has raised more than £62 million ($84 million) equity investment, including a £50 million Series B in 2022, with venture investors including British Patient Capital and Cambridge Innovation Capital (CIC). The company has also received financial support from the USA-based Crohn’s and Colitis Foundation.